A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain
A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain
复制标题
DOI：
10.1016/j.pain.2007.01.020
复制
发表时间：
2007-05-01
期刊：
影响因子：
7.4
通讯作者：
Katz, Joel
中科院分区：
文献类型：
--
作者：
Goldberg, Robert J.;Katz, Joel
40%到60%的美国人使用补充和替代医学来控制医疗状况，预防疾病，促进健康和福祉。Omega-3多不饱和脂肪酸（Omega-3 PUFAs）已被用于治疗与几种炎症相关的关节疼痛。我们对17项随机对照试验进行了荟萃分析，评估了omega-3 PUFAs对类风湿关节炎或继发于炎症性肠病和痛经的关节疼痛的缓解作用。meta分析采用Cochrane Review Manager 4.2.8进行。使用标准化平均差异（SMDs）作为效应大小衡量的六个独立结果：(1)患者评估疼痛，(2)医生评估疼痛，(3)晨僵持续时间，(4)疼痛和/或压痛关节的数量，(5)里奇关节指数，(6)非选择性非甾体抗炎药的使用。补充omega-3 PUFAs 3-4个月可降低患者报告的关节疼痛强度（SMD: -0.26; 95% CI: -0.49至-0.03,p = 0.03）、晨僵分钟（SMD: -0.43; 95% CI: -0.72至-0.15,p = 0.003）、疼痛和/或压痛关节数量（SMD: -0.29; 95% CI: -0.48至-0.10,p = 0.003）和非甾体抗炎药消耗（SMD: -0.40; 95% CI: -0.72至-0.08,p = 0.01）。在3-4个月时，医生评估的疼痛（SMD: -0.14; 95% CI: -0.49至0.22,p = 0.45）或Ritchie关节指数（SMD: 0.15; 95% CI: -0.19至0.49,p = 0.40）未发现显著影响。结果表明，omega-3 PUFAs是类风湿性关节炎、炎症性肠病和痛经相关关节疼痛的一种有吸引力的辅助治疗方法。(c) 2007年国际疼痛研究协会。Elsevier B.V.版权所有。
Between 40% and 60% of Americans use complementary and alternative medicine to manage medical conditions, prevent disease, and promote health and well-being. Omega-3 polyunsaturated fatty acids (omega-3 PUFAs) have been used to treat joint pain associated with several inflammatory conditions. We conducted a meta-analysis of 17 randomized, controlled trials assessing the pain relieving effects of omega-3 PUFAs in patients with rheumatoid arthritis or joint pain secondary to inflammatory bowel disease and dysmenorrhea. Meta-analysis was conducted with Cochrane Review Manager 4.2.8. for six separate outcomes using standardized mean differences (SMDs) as a measure of effect size: (1) patient assessed pain, (2) physician assessed pain, (3) duration of morning stiffness, (4) number of painful and/or tender joints, (5) Ritchie articular index, and (6) nonselective nonsteroidal anti-inflammatory drug consumption. Supplementation with omega-3 PUFAs for 3-4 months reduces patient reported joint pain intensity (SMD: -0.26; 95% CI: -0.49 to -0.03, p = 0.03), minutes of morning stiffness (SMD: -0.43; 95% CI: -0.72 to -0.15, p = 0.003), number of painful and/or tender joints (SMD: -0.29; 95% CI: -0.48 to -0.10, p = 0.003), and NSAID consumption (SMD: -0.40; 95% CI: -0.72 to -0.08, p = 0.01). Significant effects were not detected for physician assessed pain (SMD: -0.14; 95% CI: -0.49 to 0.22, p = 0.45) or Ritchie articular index (SMD: 0.15; 95% CI: -0.19 to 0.49, p = 0.40) at 3-4 months. The results suggest that omega-3 PUFAs are an attractive adjunctive treatment for joint pain associated with rheumatoid arthritis, inflammatory bowel disease, and dysmenorrhea. (c) 2007 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.